Neutrophils migrate into the bowel lumen as a result of an inflammatory process, and the level of fecal calprotectin strongly correlates with the degree of intestinal inflammation. 
INTRODUCTION
Fecal calprotectin has been proposed as a candidate diagnostic marker for discrimination between IBD and IBS. Calprotectin is a heterodimer of the calcium-binding proteins S100A8 and S100A9 and is present mainly in neutrophils. 1 www.irjournal.org a reliable alternative to the more time-consuming ELISA methods. 21, 22 Nonetheless, these calprotectin test kits vary in characteristics, and few data are available regarding clinical comparison. A comparison of different calprotectin test kits may help clinicians in choosing the appropriate assay. We designed this study to evaluate the initial diagnostic ability of three fecal calprotectin kits−Quantum Blue ® Calprotectin, EliA TM Calprotectin, and RIDASCREEN ® Calprotectin−in different bowel diseases. Furthermore, we tested whether the results produced by these fecal calprotectin kits correlate with disease activity and location of CD or UC.
METHODS

Subjects
We screened 52 patients who visited Severance Hospital from July to December 2014 for a workup because of abdominal pain, changes in bowel habits, and/or anorectal bleeding. We excluded patients who met any of the following criteria: incomplete colonoscopy, inability to collect fecal samples, colorectal cancer, history of bowel resection, an uncertain diagnosis after colonoscopy, or regular intake of aspirin and/or NSAIDs. Of a total of 52 screened patients, 11 were excluded: two for a lack of fecal samples, one for colorectal cancer, and eight for unclear diagnoses (Fig. 1) . Finally, 41 patients were enrolled in this study.
The patients were classified into three groups: IBD (CD, UC, and intestinal Behçet's disease), IBS, and "other colitis." The latter group was defined as patients with a bowel disease other than IBD and IBS and included patients with infectious colitis and intestinal tuberculosis. The diagnosis of a bowel disease was established on the basis of a clinical history, laboratory results, endoscopic findings, pathology, and radiologic analyses according to the diagnostic criteria. We also assessed disease severity using CDAI in patients with CD and the Mayo score in patients with UC. CRP was quantified by an immunoturbidimetric method and the cutoff was 8 mg/L. All the enrolled patients underwent complete colonoscopy. The data were collected in a prospective manner and analyzed retrospectively.
The study protocol adheres to the 1975 Declaration of Helsinki guidelines and was approved by the Institutional Review Board of Yonsei University College of Medicine (approval number: 4-2015-1117). Each participant or legal guardian provided written informed consent for diagnosis and treatment. 
Fecal Calprotectin
Statistical Analysis
The comparison among the three different calprotectin test kits was conducted using Passing and Bablok regression 
RESULTS
Patients' Characteristics
A total of 41 patients were analyzed in this study. Clinical characteristics of these patients are shown in Table 1 . Twelve of the patients with CD had ileocolonic involvement, one had colonic involvement, and five had ileal involvement. Of the patients with UC, five had proctitis, and six had pancolitis.
Mean disease activity of CD patients was 199.3 points (range, 133−393 points). There were 14 patients (78%) with CDAI >150. Mean disease activity among UC patients was 6.4 (range, 3−10). Five patients (45%) had Mayo scores of 3 to 5 (mildly active disease), and six patients (55%) had scores of 6 to 10 (moderately active disease).
The "other colitis" group consisted of four patients with infectious colitis and one patient with intestinal tuberculosis. Endoscopic findings revealed that the patients with infectious colitis had mucosal redness, erosions, and/or ulcers, and the patient with intestinal tuberculosis had circular ulcers with scars. 
Comparison of the Methods
Test Characteristics of Fecal Calprotectin and CRP
The results of quantitative assays for fecal calprotectin are presented in Fig. 3 . The mean calprotectin level according to Quantum Blue ® was 3,384±3,450 mg/g (range, 218−9,960 mg/g) in IBD, 120±190 mg/g (range, 30−459 mg/g) in IBS, and 
Test Performance of the Three Calprotectin Kits and CRP Assay
The test performance (sensitivity/specificity/positive predictive values/negative predictive values) and overall accuracy in distinguishing between IBD and IBS or "other colitis" is summarized in Table 2 . For differentiation of IBD from IBS, the overall accuracy was 97%/94%/84%/58% for Quantum Blue ® , EliA TM , RIDASCREEN ® , and CRP, respectively. For discrimination of IBD and "other colitis, " the overall accuracy was 91%/89%/76%/58% for Quantum Blue ® , EliA TM , RIDAS-CREEN ® , and CRP, respectively. Neither fecal calprotectin levels nor the CRP levels were helpful for differentiation of IBS and "other colitis" (accuracy, 22%−50%).
Correlation of Fecal Calprotectin Levels with Disease Activity among Patients with IBD
Data on the correlation between fecal calprotectin levels determined by the three kits and disease activity are depicted in Fig. 4 . In patients with CD, Quantum Blue 
Correlation of Fecal Calprotectin Levels with the Disease Location in Patients with IBD
We also explored the relation between fecal calprotectin levels and the disease location in patients with IBD (Fig.  5) . CD was located in the ileum in five patients, in the colon in one patient, and in the ileocolon in 12 patients. The mean calprotectin level according to Quantum Blue ® was 1,156±975 mg/g (range, 256−2,250 mg/g) in the ileum, 4,450 mg/g in the colon, and 5,769±3,192 mg/g (range, 1,555−9,960 mg/g) in the ileocolon. According to EliA TM , the mean calprotectin concentration was 569±576 mg/g (range, 53−1,471 mg/g) in the ileum, 2,103 mg/g in the colon, and 2,202±834 mg/g (range, 833−3,000 mg/g) in the ileocolon. According to RIDASCREEN ® , the mean calprotectin concentration was 214±335 mg/g (range, 0−800 mg/g) in the ileum, 709 mg/g in the colon, and 796±13 mg/g (range, 758−800 mg/g) in the ileocolon. According to all three fecal calprotectin kits, fecal calprotectin levels were significantly higher in CD patients with ileocolonic involvement than in CD patients with ileal involvement (all P=0.004). CDAI did not differ statistically significantly when stratified by disease location (all P>0.05). UC was identified as a type of proctitis in five patients, and pancolitis in six patients. The mean calprotectin level according to Quantum Blue ® was 2,166±3,817 mg/g (range, 218−8,990 mg/g) in proctitis and 2,353±3,742 mg/g (range, 376−9,000 mg/g) in pancolitis. According to EliA TM , the mean calprotectin concentration was 947±1,199 mg/g (range, 116−3,000 mg/g) in proctitis and 1,515±1,273 mg/g (range, 283−3,000 mg/g) in pancolitis. According to RIDASCREEN ® , the mean calprotectin concentration was 235±328 mg/g (range, 0−800 mg/g) in proctitis and 226±295 mg/g (range, 0−800 mg/g) in pancolitis. For all three kits, fecal calprotectin levels of patients with UC did not differ by disease location. The Mayo score was higher in pancolitis UC than in proctitis UC (7.7±2.1 vs. 4.8±1.5, respectively, P =0.033). In two patients with intestinal Behçet' s disease, one patient' s lesion was located in the ileocecal valve, and the other patient' s lesions were located in the ileocecal valve, terminal ileum, and colon. Calprotectin levels of the former and latter were 736 mg/g and 1,128 mg/g according to Quantum Blue ® , 47 mg/g and 500 mg/g according to EliA TM , and untestable (due to a lack of fecal samples) and above 800 mg/g according to RI-DASCREEN ® , respectively.
DISCUSSION
Calprotectin, which was first described in 1980, has been proposed as a possible diagnostic marker of IBD. 23 Recently, a new quantitative enzyme immunoassay, the EliA TM calprotectin assay, was developed, and Oyaert et al. 22 compared this assay with the point-of-care test among 183 patients with suspected IBD. Test performance of the EliA TM calprotectin assay was statistically equivalent to that of the point-of-care test. Another quantitative enzyme immunoassay, the RI-DASCREEN ® calprotectin assay, has not been validated in patients with suspected IBD. The present study compared these three fecal calprotectin kits to evaluate their initial diagnostic ability in patients with IBD, IBS, or "other colitis. " All three fecal calprotectin kits were superior to CRP in distinguishing IBD from IBS or "other colitis." Overall accuracy for differentiating IBD from IBS or "other colitis" was the best for Quantum Blue ® Calprotectin (97%/91%), followed by EliA TM Calprotectin (94%/89%) and RIDASCREEN ® Calprotectin (84%/76%). Some articles about a comparison of calprotectin test kits were published recently. Mirsepasi-Lauridsen et al. 24 compared three ELISA calprotectin tests among IBD patients and reported that the specificity of CALPRO, EK-CAL, and HK325 is 96%, 74%, and 28%, respectively. Therefore, the three calprotectin assays tested in the present study are comparable to an ELISA for diagnostic purposes. Labaere et al. 25 compared three rapid immunochromatographic assays (including Quantum Blue ® ), two ELISAs, and one automated immunoassay (EliA TM ) in terms of diagnosis and followup of IBD. Sensitivity and specificity for the diagnosis of IBD were 83% and 68% for Quantum Blue ® and 75% and 95% for EliA TM , respectively. The present study revealed similar clinical performance.
On the other hand, efficacy of fecal-calprotectin kits does not seem to be satisfactory in discriminating IBD from the "other colitis" group, considering the low specificity observed (all 40%). This is probably because the present study has a small sample size, and the study population is heterogeneous in terms of diagnosis and severity of the diseases. If the sample size of the "other colitis" group were larger, then the accuracy of fecal calprotectin kits might decrease as reported in another study. 26 The three fecal calprotectin kits
were not statistically helpful in discriminating between IBS and "other colitis" although calprotectin levels of patients with "other colitis" were found to be numerically higher than those of patients with IBS, as reported in other studies. According to all three kits, fecal calprotectin levels were significantly higher for ileocolonic involvement than for ileal involvement (all P-values, 0.004). (B) UC. For all three kits, fecal calprotectin levels did not differ by disease location. www.irjournal.org in patients with UC than in patients with CD. Costa et al. 27 reported that fecal calprotectin shows a higher correlation with disease activity of UC than with that of CD. We also evaluated the correlation between fecal calprotectin levels and disease location in patients with IBD. There was a significant difference in calprotectin levels between CD patients with ileocolonic involvement and those with ileal involvement. This result is consistent with a report by Schoepfer et al., 28 who studied the correlation of fecal calprotectin with the simple endoscopic score for CD among 140 patients with CD. Nevertheless, a comparison of colonic involvement with other affected locations must be confirmed in studies with a larger sample size because only one patient in the present study had colonic involvement. ). Finally, when we evaluated the correlation between different calprotectin kits, the correlation coefficients were high, but when we performed regression analysis, significant differences were observed. This finding is in line with the data reported in other studies. 25, 29 Therefore, as authors of those studies pointed out, direct comparison of absolute calprotectin levels between different kits is inappropriate, and the use of the same kit is desirable during the follow-up of patients with IBD. This study has several limitations. First, this study has a relatively small sample size. Therefore, larger studies will be necessary to confirm our results. Second, colonic involvement was present in only one patient with CD, and this situation limited the comparison between colonic involvement and other affected locations. Nevertheless, the trends and results of analysis regarding correlation of fecal calprotectin with the disease location are consistent with data from other studies. 21 In conclusion, fecal calprotectin tests are useful for distinguishing IBD from IBS or "other colitis" (in the descending order of performance): Quantum Blue ® Calprotectin, EliA TM Calprotectin, and RIDASCREEN ® Calprotectin.
